Serological response to a third booster dose of BNT162b2 COVID-19 vaccine among seronegative cancer patients.

Although limited by the small sample size, our findings suggest that a third (booster) dose administered to patients with cancer, who remain seronegative despite two doses of BNT162b2, may be efficacious in eliciting an antibody response.